SCHEMBL27186352

SCHEMBL27186352

CC(NC(=O)c1cn(C2CCN(S(C)(=O)=O)CC2)c(=O)c2c[nH]nc12)c1cccc2c1CCC2(F)F

nearest known ligand 0.38

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
▸ KRAS P01116 9/20 0.38
▸ SOS1 Q07889 9/20 0.38
▸ ALDH1A1 P00352 2/20 0.32
▸ MAPK1 P28482 1/20 0.31
▸ L3MBTL1 Q9Y468 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27186348 1.00 KRAS (0.38) KRASSOS1ALDH1A1MAPK1L3MBTL1
SCHEMBL27186130 0.90 SOS1 (0.39) KRASSOS1
SCHEMBL27186125 0.90 SOS1 (0.39) KRASSOS1
SCHEMBL27186887 0.89 KRAS (0.40) KRASSOS1
SCHEMBL27186885 0.89 KRAS (0.40) KRASSOS1
SCHEMBL29844254 0.88 KRAS (0.40) KRASSOS1
SCHEMBL27186145 0.83 KRAS (0.36) KRASSOS1
SCHEMBL27186149 0.83 KRAS (0.36) KRASSOS1
SCHEMBL27186367 0.83 SOS1 (0.36) KRASSOS1
SCHEMBL27186234 0.83 SOS1 (0.36) KRASSOS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240109887-A1 NOVEL SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AS SOS1 INHIBITORS VIVA STAR BIOSCIENCES (SUZHOU) CO., LTD. (CN) 2024-04-04 — — US disclosed
WO-2022187266-A1 NOVEL SUBSTITUTED BICYCLI AZA-HETEROCYCLES AS SOS1 INHIBITORS VIVA STAR BIOSCIENCES (SUZHOU) CO., LTD. (CN) 2022-09-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240109887-A1 NOVEL SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AS SOS1 INHIBITORS SOS1, SOS2, KSR1 KRAS 10/4885SOS1 1/4885ALDH1A1 3733/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback